Pacira Biosciences, Inc. (PCRX)
PCRX Stock Price Chart
Key Info
| Market Cap | 2.70B |
| Revenue (ttm) | 421.10M |
| Net Income (ttm) | 126.12M |
| Shares Out | 42.93M |
| EPS (ttm) | 2.93 |
| PE Ratio | 20.68 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 4 |
| Last Price | $60.61 |
| Previous Close | $62.03 |
| Change ($) | -1.42 |
| Change (%) | -2.29% |
| Day's Open | 62.15 |
| Day's Range | 60.13 - 62.18 |
| Day's Volume | 313,066 |
| 52-Week Range | 28.40 - 66.26 |
PCRX Stock News
PARSIPPANY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Confe...
The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in ...
--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachia...
-- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 -- -- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 --
PARSIPPANY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at ...
Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript
Pacira (PCRX) delivered earnings and revenue surprises of 3.03% and 1.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET --
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
--The Pacira Innovation and Training Center of Tampa will provide clinicians with a flexible environment for hands-on learning-- PARSIPPANY, N.J., and TAMPA, Fla., Oct. 21, 2020 (GLOBE NEWSWIR...
Pacira BioSciences (PCRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
PARSIPPANY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. m...
Is (PCRX) Outperforming Other Medical Stocks This Year?
-- EXPAREL average daily sales at 110% of the prior year for the third quarter and 110% of the prior year for the month of September -- PARSIPPANY, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Paci...
The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
-- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery -- -- European Commission decision on the Marketing Authorization Appli...
ALPHARETTA, Ga. and PARSIPPANY, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- IPG, the industry-leading provider of surgical cost management solutions, and Pacira BioSciences, Inc. (NADSAQ: PCRX)...
PARSIPPANY, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 H.C. Wainwright 22nd Annual Global Investment ...
-- EXPAREL average daily sales at 111% of the prior year for the month of August 2020 -- PARSIPPANY, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a lead...
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira BioSciences's (PCRX) CEO David Stack on Q2 2020 Results - Earnings Call Transcript
Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.
Pacira (PCRX) delivered earnings and revenue surprises of -25.00% and -0.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Paci...
PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference a...
– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery –
sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over
PARSIPPANY, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S...
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pacira to Pay $3.5 Million to Settle Various Claims with No Admission of Wrongdoing Pacira to Pay $3.5 Million to Settle Various Claims with No Admission of Wrongdoing
Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.
Top Ranked Momentum Stocks to Buy for July 21st
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Top Ranked Momentum Stocks to Buy for July 10th
PARSIPPANY, N.J., July 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior not...
Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic.
Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.
PARSIPPANY, N.J., July 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $300.0 million a...
-- EXPAREL average daily sales return to year-over-year growth for month of June 2020 -- -- EXPAREL average daily sales return to year-over-year growth for month of June 2020 --
As of late, it has definitely been a great time to be an investor of Pacira BioSciences
Pacira (PCRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
-- Orthopedic co-promotion agreement to conclude in January 2021 -- -- Significantly improves Pacira economics related to EXPAREL --
Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.
PARSIPPANY, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 BMO Prescriptions for Success Healthcare Confer...
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q1 2020 Results - Earnings Call Transcript
Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.
Pacira (PCRX) delivered earnings and revenue surprises of 65.62% and 4.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
About PCRX
Pacira BioSciences provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold tempera... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Feb 3, 2011 |
| CEO David M. Stack | Employees 606 |
| Stock Exchange NASDAQ | Ticker Symbol PCRX |
Financial Performance
In 2019, PCRX's revenue was $421.03 million, an increase of 24.83% compared to the previous year's $337.28 million. Losses were -$11.02 million, 2,238.9% more than in 2018.
Analyst Forecasts
According to 16 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is 66.38, which is an increase of 9.52% from the latest price.